NanoViricides (NNVC) Competitors $1.49 +0.04 (+2.76%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsTrends NNVC vs. ALXO, PMVP, GNLX, CLSD, IKNA, ENTX, IMAB, ELYM, GBIO, and HOWLShould you be buying NanoViricides stock or one of its competitors? The main competitors of NanoViricides include ALX Oncology (ALXO), PMV Pharmaceuticals (PMVP), Genelux (GNLX), Clearside Biomedical (CLSD), Ikena Oncology (IKNA), Entera Bio (ENTX), I-Mab (IMAB), Eliem Therapeutics (ELYM), Generation Bio (GBIO), and Werewolf Therapeutics (HOWL). These companies are all part of the "pharmaceutical products" industry. NanoViricides vs. ALX Oncology PMV Pharmaceuticals Genelux Clearside Biomedical Ikena Oncology Entera Bio I-Mab Eliem Therapeutics Generation Bio Werewolf Therapeutics ALX Oncology (NASDAQ:ALXO) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Which has more risk and volatility, ALXO or NNVC? ALX Oncology has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Do institutionals & insiders hold more shares of ALXO or NNVC? 98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 33.4% of ALX Oncology shares are owned by company insiders. Comparatively, 4.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ALXO or NNVC more profitable? NanoViricides' return on equity of -84.63% beat ALX Oncology's return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -93.02% -70.67% NanoViricides N/A -84.63%-76.49% Do analysts recommend ALXO or NNVC? ALX Oncology presently has a consensus target price of $8.50, indicating a potential upside of 424.69%. Given ALX Oncology's stronger consensus rating and higher probable upside, equities analysts plainly believe ALX Oncology is more favorable than NanoViricides.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50NanoViricides 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation & earnings, ALXO or NNVC? NanoViricides is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$160.80M-$2.98-0.54NanoViricidesN/AN/A-$8.29M-$0.76-1.96 Does the MarketBeat Community favor ALXO or NNVC? ALX Oncology received 49 more outperform votes than NanoViricides when rated by MarketBeat users. Likewise, 62.82% of users gave ALX Oncology an outperform vote while only 0.00% of users gave NanoViricides an outperform vote. CompanyUnderperformOutperformALX OncologyOutperform Votes4962.82% Underperform Votes2937.18% NanoViricidesOutperform VotesNo VotesUnderperform Votes57100.00% Does the media favor ALXO or NNVC? In the previous week, ALX Oncology had 12 more articles in the media than NanoViricides. MarketBeat recorded 12 mentions for ALX Oncology and 0 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.00 beat ALX Oncology's score of -0.17 indicating that NanoViricides is being referred to more favorably in the news media. Company Overall Sentiment ALX Oncology Neutral NanoViricides Neutral SummaryALX Oncology beats NanoViricides on 11 of the 15 factors compared between the two stocks. Ad ProsperityPubThis Indicator called BOTH NVDA ralliesRarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. Get NanoViricides News Delivered to You Automatically Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NNVC vs. The Competition Export to ExcelMetricNanoViricidesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$20.78M$6.57B$5.12B$19.18BDividend YieldN/A2.98%4.91%3.59%P/E Ratio-1.9610.5991.3441.28Price / SalesN/A195.381,116.5917.59Price / CashN/A57.1642.6421.28Price / Book1.545.104.795.32Net Income-$8.29M$151.51M$120.07M$989.88M7 Day Performance0.68%-2.15%-1.89%-3.54%1 Month Performance16.41%-3.14%11.45%-3.68%1 Year Performance40.57%11.50%30.61%12.14% NanoViricides Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NNVCNanoViricidesN/A$1.49+2.8%N/A+36.7%$20.78MN/A-1.9620High Trading VolumeALXOALX Oncology3.192 of 5 stars$1.56+7.2%$10.67+586.0%-87.7%$82.02MN/A-0.4940Analyst ForecastNews CoverageGap UpPMVPPMV Pharmaceuticals1.7944 of 5 stars$1.58flat$5.80+267.1%-34.5%$81.77MN/A0.0050Positive NewsGNLXGenelux0.8843 of 5 stars$2.33flat$18.25+683.3%-82.9%$80.47M$8,000.00-2.4510CLSDClearside Biomedical2.8771 of 5 stars$1.05+2.5%$5.33+410.4%-12.8%$79.25M$8.23M-2.2930News CoverageIKNAIkena Oncology2.8725 of 5 stars$1.64-0.6%$3.00+82.9%-20.5%$79.14M$659,000.00-1.3470ENTXEntera Bio1.4305 of 5 stars$2.20+1.9%$10.00+354.5%+195.8%$78.72M$130,000.00-8.3120IMABI-Mab2.5162 of 5 stars$0.95-4.6%$8.00+738.3%-38.9%$77.78M$3.27M0.0034Gap DownELYMEliem TherapeuticsN/A$2.60-7.8%N/A-27.5%$77.36MN/A-4.9120GBIOGeneration Bio2.7569 of 5 stars$1.15-1.1%$7.50+554.1%-30.0%$76.59M$18.58M-0.53150Positive NewsHOWLWerewolf Therapeutics3.757 of 5 stars$1.70+2.7%$12.00+608.0%-44.8%$75.53M$3.39M-1.0840Positive News Related Companies and Tools Related Companies ALX Oncology Alternatives PMV Pharmaceuticals Alternatives Genelux Alternatives Clearside Biomedical Alternatives Ikena Oncology Alternatives Entera Bio Alternatives I-Mab Alternatives Eliem Therapeutics Alternatives Generation Bio Alternatives Werewolf Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:NNVC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NanoViricides With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NNVC Stock Alerts